<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-12-24</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-12-24</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>64</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
Combined epigenetic therapy with FACT and BET inhibitors remodels chromatin and disrupts oncogenic transcription in Diffuse Midline Glioma.</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
*   <strong>ç¥ç»é€€è¡Œæ€§ç–¾ç—…</strong>ï¼šæ¢ç´¢ALSæ‚£è€…è¯­è¨€åŠæ‰§è¡ŒåŠŸèƒ½ä¸‹é™çš„ç»†èƒæœºåˆ¶ï¼ˆVisiumç©ºé—´è½¬å½•ç»„å­¦ï¼‰ã€‚<br />
*   <strong>è„‘è¡°è€æœºåˆ¶</strong>ï¼šè§£æå¤§è„‘è¡°è€çš„è¡¨è§‚é—ä¼ å­¦ç‰¹å¾ï¼ˆå•æ ¸ç”²åŸºåŒ–æµ‹åºï¼‰ã€‚<br />
*   <strong>è‚¿ç˜¤æ²»ç–—</strong>ï¼šç ”ç©¶NSD2é¶å‘æ²»ç–—å¯¹å‰åˆ—è…ºç™Œè€è¯æ€§çš„é€†è½¬ï¼ˆRNA-seq, Cut&amp;Tag, snATAC-seq, multiomeï¼‰ã€‚<br />
*   <strong>å„¿ç§‘è„‘è‚¿ç˜¤</strong>ï¼šè¯„ä¼°è”åˆè¡¨è§‚é—ä¼ ç–—æ³•å¯¹å¼¥æ¼«æ€§ä¸­çº¿èƒ¶è´¨ç˜¤çš„ç–—æ•ˆï¼ˆRNA-seq, ATAC-seq, Xenium, CUT&amp;RUNï¼‰ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
*   <strong>å¤šç»„å­¦æ•´åˆ</strong>ï¼šç»“åˆå•ç»†èƒå’Œç©ºé—´è½¬å½•ç»„å­¦ã€å•æ ¸ç”²åŸºåŒ–æµ‹åºã€å¤šç»„å­¦åˆ†æç­‰æŠ€æœ¯ï¼Œæ·±å…¥è§£æå¤æ‚ç”Ÿç‰©å­¦è¿‡ç¨‹ã€‚<br />
*   <strong>æ–°å‹ç–—æ³•è¯„ä¼°</strong>ï¼šåˆ©ç”¨å¤šç§é«˜é€šé‡æµ‹åºæŠ€æœ¯ï¼ˆå¦‚Visium, Xenium, Nascent RNA-Seq, CUT&amp;RUNï¼‰è¯„ä¼°è”åˆè¡¨è§‚é—ä¼ ç–—æ³•çš„æ•ˆæœã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ä¸€é¡¹æ–°å‹è¯ç‰©NU-9æœ‰æœ›åœ¨é˜¿å°”èŒ¨æµ·é»˜ç—…æ—©æœŸï¼ˆè®°å¿†ä¸§å¤±å‰ï¼‰é˜»æ–­ç–¾ç—…è¿›å±•ï¼›ç§‘å­¦å®¶é¦–æ¬¡åœ¨å®éªŒå®¤æˆåŠŸåˆæˆäº†å…·æœ‰å¤æ‚ç»“æ„çš„æŠ—ç™Œåˆ†å­verticillin Aã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- é˜¿å°”èŒ¨æµ·é»˜ç—…æ—©æœŸæœºåˆ¶ä¸å¹²é¢„<br />
- å¤æ‚å¤©ç„¶äº§ç‰©çš„å…¨åˆæˆä¸åº”ç”¨<br />
- å•ç»†èƒRNAæµ‹åºæŠ€æœ¯åœ¨åŸºå› è°ƒæ§ç ”ç©¶ä¸­çš„åº”ç”¨</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- ASPENæ–¹æ³•å¢å¼ºå•ç»†èƒRNAæµ‹åºä¸­ç­‰ä½åŸºå› åŠ¨åŠ›å­¦æ£€æµ‹èƒ½åŠ›ã€‚<br />
- CRISPRiç­›é€‰ä¸RNAæµ‹åºç»“åˆï¼Œæ­ç¤ºä¸é˜¿å°”èŒ¨æµ·é»˜ç—…ç›¸å…³çš„åŸºå› è°ƒæ§ç½‘ç»œã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (60æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE313918 è‚Œèç¼©ä¾§ç´¢ç¡¬åŒ–ç—‡ä¸­è¯­è¨€å’Œæ‰§è¡ŒåŠŸèƒ½è¡°é€€çš„å·®å¼‚æ€§ç»†èƒæœºåˆ¶ [Visium ç©ºé—´è½¬å½•ç»„å­¦]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šspatialã€Visiumã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : C Jackson ; A Daly ; C Roque ; J Petrescu ; H PhatnaniSeries Type : OtherOrganism : Homo sapiensHalf of all amyotrophic lateral sclerosis (ALS) patients demonstrate a spectrum of cognitive and behavioral changes over the course of the disease, but the mechanisms underlying this heterogeneity remain unclear. We assemble a high-resolution cellular map of prefrontal cortex regions of the ALS brain by integrating spatial and single-nucleus transcriptomic profiles of a cognitively stratified ALS patient cohort that includes non-neuropathological controls. We find cellular programs characteristic of ALS, including a frequent gliotic response. We also find that executive and language cognitive impairments differ from ALS without cognitive impairment, and from each other, in the extent and pattern of neuronal dysregulation and neuron-glial interactions across different brain regions. These findings reveal a relationship between cognitive phenotype and prefrontal cortex dysfunction in ALS.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313918" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE169273 é€šè¿‡å•æ ¸ç”²åŸºåŒ–æµ‹åºç ”ç©¶å¤§è„‘è¡°è€çš„è¡¨è§‚é—ä¼ ç‰¹å¾ [DHC-18mo-m-002]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šagingã€sequencingã€epigeneticã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Wei Tian ; Anna Bartlett ; Jordan Altshul ; Rosa Gomez Castanon ; Joseph R Nery ; Jacinta D Lucero ; Julia K Osteen ; Huaming Chen ; M M Behrens ; Joseph R EckerSeries Type : Methylation profiling by high throughput sequencingOrganism : Mus musculusIllustrating aging effects on the epigenomic features of brain is critical to understand brain functional decline and neurodegeneration. Single nucleus methylation sequencing was applied to brain regions of mouse at the age of 2, 9 and 18 months. We use these data to identify the epigenomic changes with aging in mouse brains.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE169273" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE299509 è¡¨è§‚é—ä¼ ç–—æ³•è”åˆ FACT å’Œ BET æŠ‘åˆ¶å‰‚å¯é‡å¡‘æŸ“è‰²è´¨å¹¶ç ´åå¼¥æ¼«æ€§ä¸­çº¿èƒ¶è´¨ç˜¤ä¸­çš„è‡´ç™Œè½¬å½• [æ–°ç”Ÿ RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šgliomaã€regex:onco(logy|logist|gene|genic)ã€RNA-seqã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Holly Holliday ; Chelsea MayohSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensAberrant epigenetic regulation is a hallmark of Diffuse Midline Glioma (DMG), an incurable pediatric brain tumor. The H3K27M driver histone mutation leads to transcriptional dysregulation, indicating that targeting the epigenome and transcription may be key therapeutic strategies against this highly aggressive cancer. One such target is the Facilitates Chromatin Transcription (FACT) histone chaperone. We found FACT to be enriched at developmental gene promoters, coinciding with regions of open chromatin and binding motifs of core DMG regulatory transcription factors. Furthermore, FACT interacted and co-localized with the Bromodomain and Extra-Terminal Domain (BET) protein BRD4 at promoters and enhancers, suggesting functional cooperation between FACT and BRD4 in DMG. In vitro, a combinatorial therapeutic approach using the FACT inhibitor CBL0137, coupled with BET inhibition revealed potent and synergistic cytotoxicity across a range of DMG cultures. These results were recapitulated in vivo, significantly extending survival in three independent orthotopic PDX models of DMG. Mechanistically, we show that CBL0137 treatment decreased chromatin accessibility, synergizing with BET inhibition to cause broad transcriptional collapse, silencing several key oncogenes including MYC, PDGFRA, MDM4 and SOX2, as well as causing alterations to the splicing landscape. Notably, this combination also elicited immune-related effects, including activation of the interferon response and antigen presentation mechanisms in DMG cells and induction of an activated state in macrophages and T cells, as demonstrated in an immunocompetent setting with spatial transcriptomics. Altogether, our data highlights the therapeutic promise of simultaneously targeting FACT and BET proteins in DMG, offering a dual tumor-intrinsic and immune-mediated strategy for combating this devastating pediatric brain tumor.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299509" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE272131 è¡¨è§‚é—ä¼ ç–—æ³•è”åˆ FACT å’Œ BET æŠ‘åˆ¶å‰‚å¯é‡å¡‘æŸ“è‰²è´¨å¹¶ç ´åå¼¥æ¼«æ€§ä¸­çº¿èƒ¶è´¨ç˜¤ä¸­çš„è‡´ç™Œè½¬å½• [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šgliomaã€regex:onco(logy|logist|gene|genic)ã€RNA-seqã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Holly Holliday ; Nisitha Jayatilleke ; Chelsea Mayoh ; Xinyi GuoSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensAberrant epigenetic regulation is a hallmark of Diffuse Midline Glioma (DMG), an incurable pediatric brain tumor. The H3K27M driver histone mutation leads to transcriptional dysregulation, indicating that targeting the epigenome and transcription may be a key therapeutic strategy against this highly aggressive cancer. One such target is the Facilitates Chromatin Transcription (FACT) histone chaperone. We found FACT to be enriched at developmental gene promoters, coinciding with regions of open chromatin and binding motifs of core DMG regulatory transcription factors. Furthermore, FACT interacted and co-localized with the Bromodomain and Extra-Terminal Domain (BET) protein BRD4 at promoters and enhancers, suggesting functional cooperation between FACT and BRD4 in DMG. In vitro, a combinatorial therapeutic approach using the FACT inhibitor CBL0137, coupled with BET inhibition revealed potent and synergistic cytotoxicity across a range of DMG cultures, with H3K27M-mutant cells demonstrating heightened sensitivity. These results were recapitulated in vivo, significantly extending survival in three independent orthotopic PDX models of DMG. Mechanistically, we show that CBL0137 treatment decreased chromatin accessibility, synergizing with BET inhibition to disrupt transcription, silencing several key oncogenes including MYC, PDGFRA and MDM4, alongside alterations to the splicing landscape. Combined, these data highlight the therapeutic promise of simultaneously targeting FACT and BRD4 in DMG, proposing a novel strategy for combating this devastating pediatric brain tumor.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272131" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE272129 è¡¨è§‚é—ä¼ ç–—æ³•è”åˆ FACT å’Œ BET æŠ‘åˆ¶å‰‚å¯é‡å¡‘æŸ“è‰²è´¨å¹¶ç ´åå¼¥æ¼«æ€§ä¸­çº¿èƒ¶è´¨ç˜¤ä¸­çš„è‡´ç™Œè½¬å½• [ATAC-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šgliomaã€regex:onco(logy|logist|gene|genic)ã€ATAC-seqã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Holly Holliday ; Nisitha Jayatilleke ; Chelsea Mayoh ; Samuel E RossSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensAberrant epigenetic regulation is a hallmark of Diffuse Midline Glioma (DMG), an incurable pediatric brain tumor. The H3K27M driver histone mutation leads to transcriptional dysregulation, indicating that targeting the epigenome and transcription may be a key therapeutic strategy against this highly aggressive cancer. One such target is the Facilitates Chromatin Transcription (FACT) histone chaperone. We found FACT to be enriched at developmental gene promoters, coinciding with regions of open chromatin and binding motifs of core DMG regulatory transcription factors. Furthermore, FACT interacted and co-localized with the Bromodomain and Extra-Terminal Domain (BET) protein BRD4 at promoters and enhancers, suggesting functional cooperation between FACT and BRD4 in DMG. In vitro, a combinatorial therapeutic approach using the FACT inhibitor CBL0137, coupled with BET inhibition revealed potent and synergistic cytotoxicity across a range of DMG cultures, with H3K27M-mutant cells demonstrating heightened sensitivity. These results were recapitulated in vivo, significantly extending survival in three independent orthotopic PDX models of DMG. Mechanistically, we show that CBL0137 treatment decreased chromatin accessibility, synergizing with BET inhibition to disrupt transcription, silencing several key oncogenes including MYC, PDGFRA and MDM4, alongside alterations to the splicing landscape. Combined, these data highlight the therapeutic promise of simultaneously targeting FACT and BRD4 in DMG, proposing a novel strategy for combating this devastating pediatric brain tumor.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272129" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE169345 é€šè¿‡å•æ ¸ç”²åŸºåŒ–æµ‹åºç ”ç©¶å¤§è„‘è¡°è€çš„è¡¨è§‚é—ä¼ ç‰¹å¾ [DHC-18mo-m-003]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šagingã€sequencingã€epigeneticã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Wei Tian ; Anna Bartlett ; Jordan Altshul ; Rosa Gomez Castanon ; Joseph R Nery ; Jacinta D Lucero ; Julia K Osteen ; Huaming Chen ; M M Behrens ; Joseph R EckerSeries Type : Methylation profiling by high throughput sequencingOrganism : Mus musculusIllustrating aging effects on the epigenomic features of brain is critical to understand brain functional decline and neurodegeneration. Single nucleus methylation sequencing was applied to brain regions of both male and female mouse at the age of 2, 9 and 18 months. We use these data to identify the epigenomic changes with aging in mouse brains.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE169345" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE314260 äººç±»èº¯å¹²èƒšçŠ¶ä½“æ¨¡å‹ï¼ˆhTEMï¼‰çš„å•ç»†èƒå’Œç©ºé—´è½¬å½•ç»„å­¦</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsingle-cellã€spatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Tianming Wu ; Hao Yu ; Brian Wong ; Ling Xu ; Joaquim Vong ; Stephen DaltonSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiensHuman embryoid models enable mechanistic studies of development and disease. We generated trunk embryoids from human pluripotent stem cells that recapitulate posterior trunk formation at Carnegie stage (CS) 8-10, with patterned anterior-posterior (A-P) and dorsal-ventral (D-V) axes. These self-organizing structures comprise a ventral notochord, dorsal neural tube, floor plate and bilateral somites. Genetic and chemical perturbations of SHH signaling confirmed the notochordâ€™s central role in D-V patterning. Moreover, VANGL1/2 loss-of-function mutations recapitulated mouse phenotypes, including axial truncation and somite segmentation failure. This model enables detailed study of key developmental events that underlie posterior trunk formation and provides a promising platform for human disease modeling.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314260" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>GSE314059 åˆ©ç”¨é•¿è¯»æµ‹åºæŠ€æœ¯å¯¹å°é¼ è„‘è¿›è¡Œå•ç»†èƒå’Œäºšå‹ç‰¹å¼‚æ€§ç¿»è¯‘åˆ†æ [scRNA-Seq, longread]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€single-cellã€scRNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Samantha L Sison ; Federico Zampa ; Eric R Kofman ; Su Yeun Choi ; Pratibha Jagannatha ; Gene W Yeo ; Giordano LippiSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe brain displays the richest repertoire of post-transcriptional mechanisms regulating mRNA translation. Among these, alternative splicing has been shown to drive cell type specificity and, when disrupted, is strongly linked to neurological disorders. However, genome-wide measurements of mRNA translation with isoform-sensitivity at single-cell (sc) resolution have not been achieved. To address this, we deployed Ribo-STAMP (Surveying Ribosomal Targets by APOBEC-Mediated Profiling) coupled with long-read scRNA-sequencing (scRNA-seq) in the brain. We generated the first isoform-sensitive sc translatomes of the mouse hippocampus at postnatal day 25, discovering cell type-specific translation of 3,857 alternative transcripts across 1,641 genes, and identifying isoforms of the same genes undergoing differential translation within and across eight different cell types. We defined high and low translational states in CA1 and CA3 neurons, with synaptic and metabolic genes enriched in high states. Surprisingly, we found that CA3 exhibited higher basal translation compared to CA1, as confirmed by metabolic labeling of newly synthesized proteins and immunohistochemistry of translational machinery components. This accessible platform will expand our understanding of how cell type- and isoform-specific translation drives brain physiology and disease.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314059" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> â­ <strong>GSE308993 NSD2é¶å‘é€†è½¬æ™šæœŸå‰åˆ—è…ºç™Œçš„è°±ç³»å¯å¡‘æ€§å’Œè€è¯æ€§[æ‰¹é‡RNAæµ‹åº]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistanceã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jia J Li ; Kristjan H Gretarsson ; Michael M ShenSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusTreatment with highly potent androgen receptor signaling inhibitors (ARSIs), such as enzalutamide and abiraterone promotes lineage plasticity in metastatic castration-resistant prostate cancer (mCRPC), which results in intra-tumor heterogeneity and emergence of mCRPC subtypes. The histological transformation from adenocarcinoma to aggressive neuroendocrine prostate cancer (CRPC-NE) has been associated with a loss of dependency on lineage-survival signals, leading to targeted drug resistance. Epigenomic reprogramming might be a fundamental driver of lineage plasticity. To determine CRPC-NE vulnerabilities, we have performed image-based screening using a small library of antibodies targeting different histone marks on CRPC-NE organoids derived from genetically engineered mice. We find that the histone mark H3K36me2 and the histone methyltransferase NSD2 (also known as MMSET/WHSC1) play important roles in maintaining the state of CRPC-NE. Knockout of NSD2 or ablation of H3K36me2 using H3.3K36M oncohistone reverted CRPC-NE to CRPC-AR-like phenotype. Simultaneous profiling of the transcriptome and epigenome from single cells collected from control (sgCtrl) and NSD2 knockout (sgNSD2) organoids, or from empty vector (EV) and H3.3K36M transduced organoids confirms the lineage reversal of treatment-resistant cells and maps the re-establishment of canonical AR signaling dependency. Moreover, H3K36me2 or NSD2 depleted mouse and human CRPC-NE organoids responded to enzalutamide treatment in vitro and in vivo, suggesting a restoration of ARSI sensitivity. Most importantly, a small molecule inhibitor of NSD2, which is similar to KTX-1001 (NCT05651932), in combination with enzalutamide leads to growth suppression or apoptosis of mouse and human CRPC-NE organoids, organoids of other CRPC subtypes and xenografts in vitro and in vivo. In conclusion, inhibition of NSD2 reverses lineage plasticity and reverts the state of treatment-resistant cells back into an ARSI-sensitive state. Thus, we suggest that the combination of NSD2 inhibition with AR inhibition may represent a novel therapeutic approach for patients with CRPC-NE and other CRPC subtypes.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308993" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> â­ <strong>GSE286020 SETD6 å¯¹ E2F1 çš„ç”²åŸºåŒ–ç ´åäº† BRD4-E2F1 çš„ç»“åˆï¼Œå¹¶è°ƒèŠ‚å‰åˆ—è…ºç™Œç»†èƒä¸­çš„åŸºå› è°ƒæ§ [ChIP-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€ChIP-seqã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Gizem T Ulu ; Margarita Kublanovsky ; Michal Feldman ; Sara Weirich ; Dan Levy ; Albert JeltschSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensThe SETD6 protein lysine methyltransferase has a role in the regulation of various cellular processes including cancer initiation and progression. It methylates several cellular proteins including K117 of the E2F1 transcription factor, but the functional consequences of this methylation event are unknown. In this study, the role of SETD6 mediated E2F1 methylation on the progression of prostate cancer was investigated. We identified distinct sets of genes that are bound and upregulated by methylated and unmethylated E2F1. Genes upregulated by methylated E2F1 lead to the negative regulation of cell migration, while genes upregulated by unmethylated E2F1 have roles in cell proliferation and apoptosis. BRD4 is known to bind E2F1 acetylated at K117 and K120. Here, we demonstrate that methylation of E2F1 at K117 prevents E2F1-BRD4 binding of in vitro and in cells establishing the molecular mechanism of the differential gene regulation by methylated and unmethylated E2F1 that depends on SETD6 activity.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286020" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 50 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (4æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>ASPENâ€”â€”å•ç»†èƒRNAæµ‹åºä¸­ç­‰ä½åŸºå› åŠ¨æ€çš„ç¨³å¥æ£€æµ‹</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šNew ASPEN method enhances detection of allelic imbalance and variance in RNA sequencing data, revealing subtle gene regulation patterns in single cells...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/aspen-robust-detection-of-allelic-dynamics-in-single-cell-rna-seq/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>é˜¿å°”èŒ¨æµ·é»˜ç—…çš„çº¿ç´¢å¯èƒ½å°±éšè—åœ¨æˆ‘ä»¬çš„â€œåƒåœ¾â€DNAä¸­ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šCRISPRi screening with RNA sequencing maps functional DNA enhancers in human astrocytes, revealing gene control networks linked to Alzheimerâ€™s disease...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/clues-to-alzheimers-disease-may-be-hiding-in-our-junk-dna/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>ä¸€ç§æ–°è¯æœ‰æœ›åœ¨è®°å¿†ä¸§å¤±å¼€å§‹å‰é˜»æ­¢é˜¿å°”èŒ¨æµ·é»˜ç—…çš„å‘å±•ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šNew research suggests Alzheimerâ€™s may start far earlier than previously thought, driven by a hidden toxic protein in the brain. Scientists found that an experimental drug, NU-9, blocks this early damage in mice and reduces inflammation linked to disease progression. The treatment was given before symptoms appeared, targeting the disease at its earliest stage. Researchers say this approach could reshape how Alzheimerâ€™s is prevented and treated.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/12/251222080119.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>è¿™ç§æŠ—ç™Œåˆ†å­å†ç»50å¹´æ‰ç ”åˆ¶æˆåŠŸã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šMIT scientists have achieved the first-ever lab synthesis of verticillin A, a complex fungal compound discovered in 1970. Its delicate structure stalled chemists for decades, despite differing from related molecules by only two atoms. With the synthesis finally complete, researchers created new variants that showed strong activity against a rare pediatric brain cancer. The breakthrough could unlock an entire class of previously unreachable cancer-fighting molecules.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/12/251222044104.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA-seq</td>
<td>12</td>
</tr>
<tr>
<td>epigenetic</td>
<td>12</td>
</tr>
<tr>
<td>cancer</td>
<td>11</td>
</tr>
<tr>
<td>sequencing</td>
<td>8</td>
</tr>
<tr>
<td>single-cell</td>
<td>7</td>
</tr>
<tr>
<td>aging</td>
<td>7</td>
</tr>
<tr>
<td>resistance</td>
<td>6</td>
</tr>
<tr>
<td>tumor</td>
<td>6</td>
</tr>
<tr>
<td>glioma</td>
<td>5</td>
</tr>
<tr>
<td>regex:onco(logy</td>
<td>logist</td>
</tr>
<tr>
<td>scRNA</td>
<td>4</td>
</tr>
<tr>
<td>spatial</td>
<td>4</td>
</tr>
<tr>
<td>immune</td>
<td>4</td>
</tr>
<tr>
<td>methylation</td>
<td>4</td>
</tr>
<tr>
<td>Alzheimer</td>
<td>2</td>
</tr>
<tr>
<td>Visium</td>
<td>2</td>
</tr>
<tr>
<td>spatial transcriptomics</td>
<td>2</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>2</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>2</td>
</tr>
<tr>
<td>metabolic</td>
<td>2</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (50æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237191" target="_blank" rel="noopener noreferrer">GSE237191 NSD2é¶å‘é€†è½¬æ™šæœŸå‰åˆ—è…ºç™Œçš„è°±ç³»å¯å¡‘æ€§å’Œè€è¯æ€§[scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314805" target="_blank" rel="noopener noreferrer">GSE314805 å‰åˆ—è…ºè‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒåœ¨æ¥å—å…ç–«æ²»ç–—åå‘ç”Ÿå˜åŒ–ï¼Œè¿™äº›å˜åŒ–ç”±å‡ºç°æŠ—è‚¿ç˜¤ååº”æˆ–å…ç–«ç›¸å…³ä¸è‰¯äº‹ä»¶çš„æ‚£è€…åˆ†äº«</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299434" target="_blank" rel="noopener noreferrer">GSE299434 è¡¨è§‚é—ä¼ ç–—æ³•è”åˆ FACT å’Œ BET æŠ‘åˆ¶å‰‚å¯é‡å¡‘æŸ“è‰²è´¨å¹¶ç ´åå¼¥æ¼«æ€§ä¸­çº¿èƒ¶è´¨ç˜¤ä¸­çš„è‡´ç™Œè½¬å½• [Xenium]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272130" target="_blank" rel="noopener noreferrer">GSE272130 è¡¨è§‚é—ä¼ ç–—æ³•è”åˆ FACT å’Œ BET æŠ‘åˆ¶å‰‚å¯é‡å¡‘æŸ“è‰²è´¨å¹¶ç ´åå¼¥æ¼«æ€§ä¸­çº¿èƒ¶è´¨ç˜¤ä¸­çš„è‡´ç™Œè½¬å½• [CUT&amp;RUN]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313870" target="_blank" rel="noopener noreferrer">GSE313870 æ•´åˆç»„å­¦åˆ†æé˜æ˜äº† ANKRD9 é€šè¿‡å˜Œå‘¤ä»£è°¢é€”å¾„è°ƒæ§é¸¡åŸä»£æˆè‚Œç»†èƒ IMP ä»£è°¢çš„ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314058" target="_blank" rel="noopener noreferrer">GSE314058 å°é¼ è„‘å•ç»†èƒå’Œäºšå‹ç‰¹å¼‚æ€§ç¿»è¯‘åˆ†æ [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308575" target="_blank" rel="noopener noreferrer">GSE308575 NSD2é¶å‘é€†è½¬æ™šæœŸå‰åˆ—è…ºç™Œçš„è°±ç³»å¯å¡‘æ€§å’Œè€è¯æ€§ [Cut&amp;Tag]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292146" target="_blank" rel="noopener noreferrer">GSE292146 æ˜“äºæ“ä½œçš„å°é¼  TNBC æ¨¡å‹æ•æ‰åˆ°äº†å¼‚è´¨æ€§è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒä»¥åŠå¯¹ PD-L1 é˜»æ–­çš„é€‚åº”æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291126" target="_blank" rel="noopener noreferrer">GSE291126 æ˜“äºæ“ä½œçš„å°é¼  TNBC æ¨¡å‹æ•æ‰åˆ°äº†å¼‚è´¨æ€§è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒä»¥åŠå¯¹ PD-L1 é˜»æ–­çš„é€‚åº”æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290815" target="_blank" rel="noopener noreferrer">GSE290815 æ˜“äºæ“ä½œçš„å°é¼  TNBC æ¨¡å‹æ•æ‰äº†è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒçš„å¼‚è´¨æ€§ä»¥åŠå¯¹ PD-L1 é˜»æ–­çš„é€‚åº”æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286198" target="_blank" rel="noopener noreferrer">GSE286198 SETD6ä»‹å¯¼çš„E2F1ç”²åŸºåŒ–ç ´åBRD4-E2F1ç»“åˆå¹¶è°ƒèŠ‚å‰åˆ—è…ºç™Œç»†èƒä¸­çš„åŸºå› è¡¨è¾¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281998" target="_blank" rel="noopener noreferrer">GSE281998 ç»†èƒå¤–åŸºè´¨è›‹ç™½1å¡‘é€ è‚¾è„çº¤ç»´åŒ–å¾®ç¯å¢ƒçš„ä»£è°¢å’Œç©ºé—´åŠ¨æ€</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237197" target="_blank" rel="noopener noreferrer">GSE237197 NSD2é¶å‘æ²»ç–—é€†è½¬æ™šæœŸå‰åˆ—è…ºç™Œçš„è°±ç³»å¯å¡‘æ€§å’Œè€è¯æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237196" target="_blank" rel="noopener noreferrer">GSE237196 NSD2é¶å‘é€†è½¬æ™šæœŸå‰åˆ—è…ºç™Œçš„è°±ç³»å¯å¡‘æ€§å’Œè€è¯æ€§[snATAC-seqå’Œå¤šç»„snATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237195" target="_blank" rel="noopener noreferrer">GSE237195 NSD2é¶å‘é€†è½¬æ™šæœŸå‰åˆ—è…ºç™Œçš„è°±ç³»å¯å¡‘æ€§å’Œè€è¯æ€§[å¤šç»„snRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314569" target="_blank" rel="noopener noreferrer">GSE314569 è‚ é“èŒç¾¤ç¼ºå¤±å¯¹å¦Šå¨ å°é¼ èƒç›˜-è„‘è½´çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306072" target="_blank" rel="noopener noreferrer">GSE306072 ç ”ç©¶è¯„ä¼°äº†ç”¨è¡¨è§‚é—ä¼ æŠ‘åˆ¶å‰‚æ²»ç–—çš„è‚¿ç˜¤ç»†èƒä»¥åŠåœè¯åè‚¿ç˜¤ç»†èƒçš„åŸºå› è¡¨è¾¾å˜åŒ–ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314020" target="_blank" rel="noopener noreferrer">GSE314020 æœ‰ä¸åˆ†è£‚ç»†èƒä¸­è½¬å½•ç»„çš„å…¨å±€ç¨³å®šæ€§ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313694" target="_blank" rel="noopener noreferrer">GSE313694 è„‘è†œç˜¤çš„ç©ºé—´è½¬å½•ç»„åˆ†æï¼ˆVisiumï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305964" target="_blank" rel="noopener noreferrer">GSE305964 å¤§é¼ ç›†è…”ç¥ç»æŸä¼¤å¼•èµ·çš„ç¥ç»æºæ€§è†€èƒ±çš„å•ç»†èƒRNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296159" target="_blank" rel="noopener noreferrer">GSE296159 æ·±åº¦é¶å‘æµ‹åºæ­ç¤ºåŸå‘æ€§å’Œå¤å‘æ€§é«˜çº§åˆ«æµ†æ¶²æ€§åµå·¢ç™Œä¹‹é—´çš„åŸºå› ç»„å·®å¼‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293642" target="_blank" rel="noopener noreferrer">GSE293642 æ—¥æœ¬è¡€å¸è™«ç”Ÿæ®–å‘è‚²è¿‡ç¨‹ä¸­çš„å•ç»†èƒRNAæµ‹åºè°±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289108" target="_blank" rel="noopener noreferrer">GSE289108 ç‚ç—‡è„‘ä¸­ç¥ç»å…ƒå‘ç”Ÿ IFNÎ³ é©±åŠ¨çš„æŒç»­è¡¨è§‚é—ä¼ æ”¹å˜å’Œçªè§¦é‡å¡‘ [ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289107" target="_blank" rel="noopener noreferrer">GSE289107 ç‚ç—‡è„‘ä¸­ç¥ç»å…ƒå‘ç”Ÿ IFNÎ³ é©±åŠ¨çš„æŒç»­è¡¨è§‚é—ä¼ æ”¹å˜å’Œçªè§¦é‡å¡‘ [ATAC-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288606" target="_blank" rel="noopener noreferrer">GSE288606 ç¥ç»å…ƒåœ¨ç‚ç—‡è„‘ä¸­ç»å† IFNÎ³ é©±åŠ¨çš„æŒç»­è¡¨è§‚é—ä¼ æ”¹å˜å’Œçªè§¦é‡å¡‘ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293260" target="_blank" rel="noopener noreferrer">GSE293260 æš´éœ²äºé¦™çƒŸçƒŸé›¾çš„æˆå¹´å°é¼ ç¾ä¸¸å•ç»†èƒåˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280334" target="_blank" rel="noopener noreferrer">GSE280334 é‰´å®šå·¨å™¬ç»†èƒä¾èµ–æ€§Fcer1g+é—´å……è´¨ç»†èƒä¸ºä¼¤å£æ„ˆåˆè¿‡ç¨‹ä¸­ç˜¢ç—•å½¢æˆçš„å…³é”®è°ƒèŠ‚å› å­</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275133" target="_blank" rel="noopener noreferrer">GSE275133 å°é¼ è„‘å•ç»†èƒå’Œäºšå‹ç‰¹å¼‚æ€§ç¿»è¯‘åˆ†æ [æ‰¹é‡ RNA æµ‹åº]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270776" target="_blank" rel="noopener noreferrer">GSE270776 VHL åˆæˆè‡´æ­»æ€§ç­›é€‰æ­ç¤º CBF-Î² æ˜¯ STING çš„è´Ÿè°ƒæ§å› å­ï¼ˆRNA-Seqï¼‰ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314162" target="_blank" rel="noopener noreferrer">GSE314162 æ‚äº¤æ•è· RNA-seq å®šä¹‰äº†ç«‹å…‹æ¬¡ä½“ä¸­åŸºå› è¡¨è¾¾çš„æ—¶é—´åºåˆ—</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297352" target="_blank" rel="noopener noreferrer">GSE297352 ç ”ç©¶å‘ç°ï¼Œå¯é€†æ€§ç»†èƒè¡°è€ä¸­ RNA åŠ å·¥ç¼ºé™·å’Œ ELOA ä»‹å¯¼çš„è½¬å½•å»¶ä¼¸è¡¨æ˜è¡°è€æ˜¯é€šè¿‡è½¬å½•å®ç°çš„ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285193" target="_blank" rel="noopener noreferrer">GSE285193 èƒ°è…ºç™Œæ¥æºçš„ç»†èƒå¤–å›Šæ³¡å¯¹éª¨é«“æ¥æºå·¨å™¬ç»†èƒçš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284368" target="_blank" rel="noopener noreferrer">GSE284368 ä¿ç•™èƒšèƒã€èƒšå¤–å’Œèƒšæ³¡ç”Ÿæˆæ½œèƒ½çš„åŸå§‹äººç±»å¤šèƒ½å¹²ç»†èƒçš„æ— é¥²å…»å±‚åŸ¹å…» [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE269948" target="_blank" rel="noopener noreferrer">GSE269948 ç ”ç©¶å‘ç°ï¼Œå¯é€†æ€§ç»†èƒè¡°è€ä¸­ RNA åŠ å·¥ç¼ºé™·å’Œ ELOA ä»‹å¯¼çš„è½¬å½•å»¶ä¼¸è¡¨æ˜è¡°è€æ˜¯é€šè¿‡è½¬å½•å®ç°çš„ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE269718" target="_blank" rel="noopener noreferrer">GSE269718 ç ”ç©¶å‘ç°ï¼Œå¯é€†æ€§ç»†èƒè¡°è€ä¸­ RNA åŠ å·¥ç¼ºé™·å’Œ ELOA ä»‹å¯¼çš„è½¬å½•å»¶ä¼¸è¡¨æ˜è¡°è€æ˜¯é€šè¿‡è½¬å½•å®ç°çš„ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE269717" target="_blank" rel="noopener noreferrer">GSE269717 ç ”ç©¶å‘ç°ï¼Œå¯é€†æ€§ç»†èƒè¡°è€ä¸­ RNA åŠ å·¥ç¼ºé™·å’Œ ELOA ä»‹å¯¼çš„è½¬å½•å»¶ä¼¸æç¤ºè¡°è€æ˜¯é€šè¿‡è½¬å½•å®ç°çš„ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE269715" target="_blank" rel="noopener noreferrer">GSE269715 ç ”ç©¶å‘ç°ï¼Œå¯é€†æ€§ç»†èƒè¡°è€ä¸­ RNA åŠ å·¥ç¼ºé™·å’Œ ELOA ä»‹å¯¼çš„è½¬å½•å»¶ä¼¸æç¤ºè¡°è€æ˜¯é€šè¿‡è½¬å½•å®ç°çš„ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311598" target="_blank" rel="noopener noreferrer">GSE311598 æˆç†Ÿè„‚è‚ªç»†èƒä¸­èŠ³çƒƒå—ä½“çš„æ¿€æ´»ä¸å½±å“å°é¼ é¥®é£Ÿè¯±å¯¼çš„è‚¥èƒ– [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311153" target="_blank" rel="noopener noreferrer">GSE311153 æˆç†Ÿè„‚è‚ªç»†èƒä¸­èŠ³çƒƒå—ä½“çš„æ¿€æ´»ä¸å½±å“å°é¼ é¥®é£Ÿè¯±å¯¼çš„è‚¥èƒ– [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE264412" target="_blank" rel="noopener noreferrer">GSE264412 3ä¾‹DIPGç—…ä¾‹çš„æ‰¹é‡RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314652" target="_blank" rel="noopener noreferrer">GSE314652 é¶å‘ mTORC2 ä¾èµ–æ€§ AKT/FOXO1/RNF125 ä¿¡å·é€šè·¯åˆ©ç”¨ c-MET æ¿€æ´»å’Œ Î²-catenin çªå˜è‚ç»†èƒç™Œçš„æ²»ç–—å¼±ç‚¹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314476" target="_blank" rel="noopener noreferrer">GSE314476 å¤–æºæ€§å¤©å†¬é…°èƒºå¯¹ç»“ç›´è‚ è‚¿ç˜¤ç”Ÿé•¿ã€17Î²-é›ŒäºŒé†‡æ°´å¹³å’ŒèŠ³é¦™åŒ–é…¶çš„æ€§åˆ«ç‰¹å¼‚æ€§å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314025" target="_blank" rel="noopener noreferrer">GSE314025 å®‰æ ¼æ›¼ç»¼åˆå¾çŒªæ¨¡å‹é¢å¶çš®è´¨å•æ ¸RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314021" target="_blank" rel="noopener noreferrer">GSE314021 æœ‰ä¸åˆ†è£‚ç»†èƒä¸­è½¬å½•ç»„çš„å…¨å±€ç¨³å®šæ€§ [PALseq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313978" target="_blank" rel="noopener noreferrer">GSE313978 è†³é£Ÿé«˜çº¤ç»´å’ŒN-æ°¨ç”²é…°è°·æ°¨é…¸é€šè¿‡è°ƒèŠ‚ä¹³é…¸æ†èŒã€è„‚è´¨ä»£è°¢ç‰©å’ŒPI3K-Aktä¿¡å·é€šè·¯æé«˜æ¯çŒªç¹æ®–æ€§èƒ½</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313951" target="_blank" rel="noopener noreferrer">GSE313951 ç¥–å…ˆç›¸å…³çš„IL-10ä¿¡å·ä¼ å¯¼å’Œå·¨å™¬ç»†èƒæ´»åŒ–è°ƒèŠ‚åŸºäºPEGçš„å¾®ç”Ÿç†ç³»ç»Ÿä¸­æˆçº¤ç»´ç»†èƒå¯¹æ°§åŒ–åº”æ¿€çš„ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313865" target="_blank" rel="noopener noreferrer">GSE313865ï¼šæ‰¬å­é²Ÿå•ç»†èƒå›¾è°±æ­ç¤ºæ´»åŒ–çŸ³é±¼ç±»çš„æ¼”åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313693" target="_blank" rel="noopener noreferrer">GSE313693 è„‘è†œç˜¤å•æ ¸RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295714" target="_blank" rel="noopener noreferrer">GSE295714 æœºæ¢°æ•æ„Ÿæ€§ TRPV4 ä¸ NF-ÎºB ä¹‹é—´çš„æ–°å‹ä¸²æ‰°æŠ‘åˆ¶è‚ºéƒ¨ç‚ç—‡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289109" target="_blank" rel="noopener noreferrer">GSE289109 ç‚ç—‡è„‘ä¸­ç¥ç»å…ƒå‘ç”Ÿ IFNÎ³ é©±åŠ¨çš„æŒç»­è¡¨è§‚é—ä¼ æ”¹å˜å’Œçªè§¦é‡å¡‘ [snRNA-Seq]</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-12-23 21:37</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>